Health Economics and Financing, Public Health Foundation of India, New Delhi, Delhi, India.
Indian Institute of Public Health - Delhi, Public Health Foundation of India, New Delhi, Delhi, India.
BMJ Open. 2019 Jan 24;9(1):e024200. doi: 10.1136/bmjopen-2018-024200.
The objective of this study was to examine the impact of medicines price regulation (Drug Price Control Order, 2013) on the market share of atorvastatin in the Indian retail market for statins.
All Indian states, January 2012 to December 2015.
Quasi-experimental-interrupted time series analysis.
Pharmaceutical sales audit data set from IMS Health (now IQVIA) for the 48-month period from January 2012 to December 2015.
Share of atorvastatin (in percentage) in the Indian market for statins in terms of sales volumes.
We observed that the price regulation notification (Drug Price Control Orders, 2013) was associated with 0.12% (p<0.001; 95% CI 0.06 to 0.18) increase in the trend of the average monthly market share of atorvastatin (5 mg and 10 mg). After 31 months of price ceilings notification, the average market share of atorvastatin was 3.41% higher than would have been expected had the price ceilings not been notified. In sensitivity analysis, with a control, our findings remain robust, we observed a 0.16% (p<0.001; 95% CI 0.08 to 0.24) rise in the trend of average monthly market share of atorvastatin (5 mg and 10 mg) as compared with the change in the control.
Price control as a public intervention did improve the relative sales of atorvastatin in the statin market in India.
本研究旨在考察药品价格管制（2013 年药品价格管制令）对阿托伐他汀在印度零售他汀类药物市场份额的影响。
所有印度邦，2012 年 1 月至 2015 年 12 月。
准实验中断时间序列分析。
来自 IMS Health（现为 IQVIA）的 48 个月的药品销售审计数据集，时间范围为 2012 年 1 月至 2015 年 12 月。
阿托伐他汀（按销售量计算）在印度他汀类药物市场的份额（以百分比表示）。
我们观察到，价格管制通知（2013 年药品价格管制令）与阿托伐他汀的平均月度市场份额趋势增加了 0.12%（p<0.001；95%置信区间 0.06 至 0.18）。在价格上限通知后的 31 个月，阿托伐他汀的平均市场份额比没有通知价格上限时高出 3.41%。在敏感性分析中，在有对照的情况下，我们的发现仍然稳健，与对照相比，阿托伐他汀的平均月度市场份额趋势上升了 0.16%（p<0.001；95%置信区间 0.08 至 0.24）。
作为一种公共干预措施的价格控制确实提高了阿托伐他汀在印度他汀类药物市场的相对销售。
